Company Information

  

Address: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
BALLYCOOLIN 
City: DUBLIN 
State:  
Zip Code: 15 
Telephone: 636-449-1830 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

(Amounts in thousands, unless otherwise noted) General Overview Avadel Pharmaceuticals PLC ("Avadel," the "Company," "we," "our," or "us") is a specialty pharmaceutical company engaged in identifying, developing, and commercializing niche branded pharmaceutical products mainly in the U.S. Our business model consists of three distinct strategies: * the development of differentiated, patent protected products through application of the Company's proprietary patented drug delivery platforms, Micropump┬« and LiquiTime┬«, that target high-value solid and liquid oral and alternative dosages forms through the U.S. Food and Drug Administration (FDA) 505(b)(2) approval process, which allows a sponsor to submit an application that doesn't depend on efficacy, safety, and toxicity data created by the sponsor.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/20171.93NA5.44
06/20170.92NA11.99
03/2017-0.24NAN/E
12/2016-1.00NAN/E
09/20160.62NA20.00

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.11Total Liab/Total Assets0.83
Net Inc/Total Assets-0.17Total Liab/Inv Cap1.11
Net Inc/Inv Cap-0.23Total Liab/Comm Equity0.53
Pretax Inc/Net Sales-0.06Interest Coverage Ratio-9.09
Net Inc/Net Sales-0.27Curr Debt/Equity0.01
Cash Flow/Net Sales0.13LTD/Equity0.01
SG&A/NetSales0.62Total Debt/Equity0.02
Asset Utilization   Liquidity  
Net Receivables Turnover10.84Quick Ratio2.85
Inventory Turnover3.83Current Ratio2.90
Inventory Day Sales0.01Net Rec/Curr Assets0.10
Net Sales/Work Cap1.27Inv/Curr Assets0.02
Net Sales/PP&E45.25  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 39.68 46.31 52.51 43.09
Cost of Goods Sold 3.79 4.56 3.90 2.59
Selling & Admin Exps 1.66 -0.80 4.84 6.98
Operating Income 26.12 34.13 33.34 17.06
Interest Exp 0.26 0.26 0.26 0.26
Pretax Income 27.60 36.30 34.45 18.08
Other Income 1.75 2.43 1.37 1.28
Net Income Bef Extraordinary ... NA NA NA NA
Net Income 21.68 28.93 25.91 4.73

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 115.61 173.80 179.21 154.20
Receivables - Total 24.08 19.29 13.46 17.84
Inventories - Total 5.87 5.75 5.41 3.26
Total Current Assets 148.93 204.35 204.61 181.19
Net Property, Plant & Equipment 3.18 3.33 3.38 3.32
Total Assets 277.43 259.16 258.69 245.48
Liabilities        
Accounts Payable 63.59 44.12 37.64 25.53
Debt in Current Liabilities 0.30 0.29 0.27 0.27
Total Current Liabilities 97.31 88.71 84.05 62.42
Long-Term Debt 0.61 0.59 0.56 0.55
Total Liabilities 180.96 182.43 199.61 203.41
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.41 0.41 0.41 0.41
Retained Earnings -254.44 -276.12 -305.05 -319.80
Treasury Stock -17.51 -14.34 NA NA
Total Stockholders' Equity 96.46 76.73 59.08 42.07
Total Liabilities and Stockholders' Equity 277.43 259.16 258.69 245.48

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -3.06 8.23 25.31 7.74
Net Cash Provided by Investing Activities 1.08 15.75 -31.99 13.46
Net Cash Provided by Financing Activities -3.93 -12.95 -0.41 0.06

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20127.53-3.23--
12/20134.18-42.92--
12/201414.98-85.47--
12/2015173.0141.80--
12/2016150.25-41.28-1.00
Growth Rates111.32----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/179029,83274.42




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.